Literature DB >> 2642969

Approaches to monitoring clinical trials.

T R Fleming1, L F Watelet.   

Abstract

In prospective clinical trials, safety and efficacy results should be monitored periodically. If early data provide convincing evidence of a superior therapeutic index for one of the treatments, then early trial termination would satisfy important ethical requirements and save valuable resources and time. The data obtained in these studies are often analyzed further to determine whether treatment effects differ in various subsets. In this paper we discuss the problems that can arise from frequently used inappropriate approaches to interim and subset analyses. The proper role of such analyses is then discussed, and valid and useful methods are described for deciding on early termination of negative as well as positive studies and for investigating subset effects.

Mesh:

Year:  1989        PMID: 2642969     DOI: 10.1093/jnci/81.3.188

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  7 in total

1.  When to stop a clinical trial.

Authors:  S J Pocock
Journal:  BMJ       Date:  1992-07-25

2.  Has adjuvant treatment of breast cancer had an unfair trial?

Authors:  I Mittra
Journal:  BMJ       Date:  1990-12-08

3.  Monitoring for lack of benefit: a critical component of a randomized clinical trial.

Authors:  Boris Freidlin; Edward L Korn
Journal:  J Clin Oncol       Date:  2008-12-08       Impact factor: 44.544

4.  Gene expression profile predicts response to the combination of tosedostat and low-dose cytarabine in elderly AML.

Authors:  Giuseppe Visani; Federica Loscocco; Mike Dennis; Eliana Zuffa; Anna Candoni; Alberto Sensi; Barbara Giannini; Gerardo Musuraca; Anna Maria Mianulli; Marino Clavio; Marco Rocchi; Davide Gibellini; Mohsen Navari; Amanda Gilkes; Pier Paolo Piccaluga; Alessandro Isidori
Journal:  Blood Adv       Date:  2020-10-27

5.  Clinical trials: discerning hype from substance.

Authors:  Thomas R Fleming
Journal:  Ann Intern Med       Date:  2010-09-21       Impact factor: 25.391

6.  Participation in clinical trials: is it state-of-the-art treatment for African Americans and other people of color?

Authors:  C R Thomas; H A Pinto; M Roach; C B Vaughn
Journal:  J Natl Med Assoc       Date:  1994-03       Impact factor: 1.798

7.  Stopping rules, interim analyses and data monitoring committees.

Authors:  D Ashby; D Machin
Journal:  Br J Cancer       Date:  1993-12       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.